Understanding the evolving safety landscape in autologous and allogeneic CAR-T therapy

Abstract

The limitations of traditional cell and secreted protein analysis methods, which are low-throughput or lack the ability to capture dynamic immune cell data, are driving the need for innovative tools to link insights on immune cell health, proliferation, and phenotype, as well as cytokine secretion profiles. In this article, an expert panel discusses the practical advantages of advanced flow cytometry over traditional methods to purify and phenotype patient immune cells, and how this approach can be used to streamline development of CAR T and CAR NK therapies.